MedTrace Logo

Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients

NCT05604131 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2026-04-08

No results posted yet for this study

Summary

The objective of this randomized, controlled pilot study is to determine the efficacy of Deferiprone to reduce the amount of free iron inside the hemorrhagic zone of myocardial infarction among hemorrhagic myocardial infarction patients.

Conditions

  • Acute Myocardial Infarction Type 1

Interventions

DRUG

Deferiprone Tablets

Deferiprone tablets are the active medication for the active arm of the study groups. Randomization will be done by investigational drug services pharmacist and intervention will be double-blinded to investigators and patients.

DRUG

Placebo

Deferiprone placebo is the non-medicated formulation for a control arm of the study groups.

Sponsors & Collaborators

  • Minneapolis Heart Institute

    collaborator OTHER

  • Rohan Dharmakumar

    lead OTHER

Principal Investigators

  • Keyur P Vora, MD FACP FACC · Medical Imaging Research Institute, Indiana University School of Medicine

  • Rohan Dharmakumar, PhD · Medical Imaging Research Institute, Indiana University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-08
Primary Completion
2029-03-31
Completion
2029-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05604131 on ClinicalTrials.gov